Alum: an old dog with new tricks

Emerging Microbes and Infections

Volumn 5, Issue 1, 2016, Pages 1-5

  Wen, Yumei ^a   Shi, Yan ^b,c  

^a FUDAN UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

alum; cancer therapy; crystals; hepatitis B; inflammasome

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; CRYOPYRIN; IMMUNOLOGICAL ADJUVANT; INFLAMMASOME; VACCINE;

ANIMAL; CHEMISTRY; HEPATITIS B; HUMAN; IMMUNOLOGY; NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; HEPATITIS B; HUMANS; INFLAMMASOMES; NEOPLASMS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; VACCINES;

EID: 85019833087     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2016.40     Document Type: Review

References (60)

1. Glenny AT,Pope CG,Waddington H,Wallace V.The antigenic value of toxoid precipitated by potassium alum. receptors control activation of adaptive immune responses.J Pathol Bacteriol1926; 29:38–45.
2. Maschmann E,Küster E,Fischer W.Über die Fähigkeit des Tonerde-Präparates B, Diphtherie-Toxin zu adsorbieren.Berichte der Deutschen Chemischen Gesellschaft1931; 64:2174–2178.
3. Ericsson H.Purification and adsorption of diphtheria toxoid.Nature1946; 158:350.
4. Cooper PD,McComb C,Steele EJ.The adjuvanticity of Algammulin, a new vaccine adjuvant.Vaccine1991; 9:408–415.
5. Jankovic D,Caspar P, et alZweig M.J Immunol1997; 159:2409–2417.
6. Pollock KG,Conacher M, et alWei XQ.Immunology2003; 108:137–143.
7. White RG,Coons AH,Connolly JM.Studies on antibody production. III. The alum granuloma.J Exp Med1955; 102:73–82.
8. Holt LB.Developments in Diphtheria Prophylaxis.London: Heinemann.1950.
9. Hutchison S,Benson RA, et alGibson VB.FASEB J2012; 26:1272–1279.
10. Munks MW,McKee AS, et alMacleod MK.Blood2010; 116:5191–5199.
11. Hansen B,Belfast M, et alSoung G.Vaccine2009; 27:888–892.
12. Hansen B,Sokolovska A, et alHogenEsch H.Vaccine2007; 25:6618–6624.
13. Romero Mendez IZ,Shi Y, et alHogenEsch H.Vaccine2007; 25:825–833.
14. Watkinson A,Soliakov A, et alGanesan A.Clin Vaccine Immunol2013; 20:1659–1668.
15. Janeway C.Immunobiology: the Immune System in Health and Disease.New York: Garland Science.2005.
16. Steinhagen F,Kinjo T, et alBode C.Vaccine2011; 29:3341–3355.
17. Schnare M,Barton GM, et alHolt AC.Nat Immunol2001; 2:947–950.
18. Gavin AL,Hoebe K, et alDuong B.Science2006; 314:1936–1938.
19. Davis BK,Wen H,Ting JP.The inflammasome NLRs in immunity, inflammation, and associated diseases.Annu Rev Immunol2011; 29:707–735.
20. Sutterwala FS,Haasken S,Cassel SL.Mechanism of NLRP3 inflammasome activation.Ann NY Acad Sci2014; 1319:82–95.
21. Li H,Nookala S,Re F.Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release.J Immunol2007; 178:5271–5276.
22. Dostert C,Guarda G, et alRomero JF.PLoS One2009; 4:e6510.
23. Hari A,Zhang Y, et alTu Z.Sci Rep2014; 4:7281.
24. Muñoz-Planillo R,Kuffa P, et alMartínez-Colón G.Immunity2013; 38:1142–1153.
25. Alfonso-Loeches S,Urena-Peralta JR, et alMorillo-Bargues MJ.Front Cell Neurosci2014; 8:216.
26. Zhou R,Yazdi AS, et alMenu P.Nature2011; 469:221–225.
27. Murakami T,Ockinger J, et alYu J.Proc Natl Acad Sci USA2012; 109:11282–11287.
28. Lee GS,Subramanian N, et alKim AI.Nature2012; 492:123–127.
29. Eisenbarth SC,Oscar RC, et alWilliam OC.Nature2008; 453:1122–1126.
30. Andreakos E,Williams RO, et alWales J.Proc Natl Acad Sci USA2006; 103:14459–14464.
31. Kawai T,Akira S.Signaling to NF-kappaB by Toll-like receptors.Trends Mol Med2007; 13:460–469.
32. Kool M,Pétrilli V, et alDe Smedt T.J Immunol2008; 181:3755–3759.
33. Franchi L,Nunez G.The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity.Eur J Immunol2008; 38:2085–2089.
34. McKee AS,Munks MW, et alMacLeod MK.J Immunol2009; 183:4403–4414.
35. Flach TL,Ng G, et alHari A.Nat Med2011; 17:479–487.
36. Matzinger P.Tolerance, danger, and the extended family.Annu Rev Immunol1994; 12:991–1045.
37. Shi Y,Evans JE,Rock KL.Molecular identification of a danger signal that alerts the immune system to dying cells.Nature2003; 425:516–521.
38. Rock KL.The ins and outs of cross-presentation.Nat Immunol2003; 4:941–943.
39. Lima H, Jr,Jacobson LS, et alGoldberg MF.Cell Cycle2013; 12:1868–1878.
40. Fink SL,Cookson BT.Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells.Infect Immun2005; 73:1907–1916.
41. McKee AS,Burchill MA, et alMunks MW.Proc Natl Acad Sci USA2013; 110:31.
42. Marichal T,Ohata K, et alBedoret D.Nat Med2011; 17:996–1002.
43. Rathinam VA,Jiang Z, et alWaggoner SN.Nat Immunol2010; 11:395–402.
44. Hornung V,Ablasser A, et alCharrel-Dennis M.Nature2009; 458:514–518.
45. Burdette DL,Monroe KM, et alSotelo-Troha K.Nature2011; 478:515–518.
46. Gao D,Wu J, et alWu YT.Science2013; 341:903–906.
47. Sun L,Wu J,Du F, et alChen X.Science2013; 339:786–791.
48. McKee AS,Burchill MA, et alMunks MW.Proc Natl Acad Sci USA2013; 110:E1122–E1131.
49. Kool M,Soullié T, et alvan Nimwegen M.J Exp Med2008; 205:869–882.
50. Shi Y,Galusha SA,Rock KL.Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model.J Immunol2006; 176:3905–3908.
51. Hari A,Ganguly A, et alMu L.Eur J Immunol2015; 45:383–395.
52. Xu DZ,Huang KL, et alZhao K.Vaccine2005; 23:2658–2664.
53. Xu DZ,Zhao K, et alGuo LM.PLoS One2008; 3:e2565.
54. Xu DZ,Wang XY, et alShen XL.J Hepatol2013; 59:450–456.
55. Wang XY,Yao X, et alWan YM.Immunol Lett2013; 149:88–92.
56. Melero I,Gaudernack G, et alGerritsen W.Nat Rev Clin Oncol2014; 11:509–524.
57. Wang B,Wang X, et alWen Y.Sci Rep2015; 5:17695.
58. Rimaniol AC,Gras G, et alVerdier F.Vaccine2004; 22:3127–3135.
59. TM; as a vaccine adjuvant: a review of safety and immunogenicity.Expert Rev Vaccines2010; 9:1135–1141.
60. Sánchez Vallecillo MF,Minguito de la Escalera MM, et alAguirre MV.J Control Release2015; 214:12–22.